DeepMed Research

Etoricoxib

Generic Name: Etoricoxib

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₅ClN_₂O_₂S

CAS Number: 202409-33-4

Unique Ingredient Identifier: WRX4NFY03R

Background: Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.

Indication: For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.

Associated Conditions: Ankylosing Spondylitis (AS), Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Moderate Pain

Clinical Trials

Preemptive Analgesia in Cruciate Reconstruction

Phase 3

Completed

Conditions: Anterior Cruciate Ligament Injury

Interventions: Drug: Celecoxib
Drug: etoricoxib

First Posted Date: 2009-11-20

Last Posted Date: 2009-11-20

Lead Sponsor: Prince of Songkla University

Target Recruit Count: 30

Registration Number: NCT01017380

Locations: 🇹🇭
Prince of Songkla University, Hat Yai, Songkhla, Thailand

COX-2 Inhibition in Allergic Asthma

Not Applicable

Completed

Conditions: Asthma

Interventions: Drug: Etoricoxib

First Posted Date: 2009-10-27

Last Posted Date: 2013-04-24

Lead Sponsor: Barbro Dahlen

Target Recruit Count: 16

Registration Number: NCT01002690

Locations: 🇸🇪
Karolinska University Hospital, Stockholm, Sweden

Etoricoxib in Acute Ankle Ligament Sprains

Phase 4

Withdrawn

Conditions: Sprain

Interventions: Device: Ankle brace
Drug: Diclofenac 50 mg tds
Drug: Etoricoxib 120 mg mane

First Posted Date: 2009-08-07

Last Posted Date: 2013-06-20

Lead Sponsor: University of Cape Town

Registration Number: NCT00954785

Locations: 🇿🇦
Kuilsriver Netcare Hospital, 33 Van Riebeeck Road, Kuilsriver, Cape Town, Western Cape, South Africa
🇿🇦
Sports Medicine Clinic, Sports Science Institute of South Africa, Cape Town, Western Cape, South Africa

Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)

Phase 1

Completed

Conditions: Pain

Interventions: Drug: etoricoxib

First Posted Date: 2009-07-23

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 36

Registration Number: NCT00945035

Etoricoxib for Postoperative Pain After Thyroid Surgery

Phase 4

Conditions: Acute Pain

Interventions: Drug: etoricoxib

First Posted Date: 2009-07-08

Last Posted Date: 2009-07-08

Lead Sponsor: Hospital Padre Hurtado

Target Recruit Count: 70

Registration Number: NCT00935116

Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis

Phase 4

Completed

Conditions: Osteoarthritis
Pain

Interventions: Drug: Sugar pill
Drug: Etoricoxib (Arcoxia)

First Posted Date: 2009-06-24

Last Posted Date: 2012-05-03

Lead Sponsor: Curtin University

Target Recruit Count: 80

Registration Number: NCT00927004

Locations: 🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia

Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder

Phase 3

Terminated

Conditions: Soft Tissue Injuries of the Shoulder
Tenosynovitis and Bursitis Affecting the Shoulder

Interventions: Drug: Etoricoxib 60 mg
Drug: Etoricoxib 90 mg

First Posted Date: 2009-04-06

Last Posted Date: 2012-07-03

Lead Sponsor: Clinica Virgen Milagrosa

Target Recruit Count: 45

Registration Number: NCT00876317

Locations: 🇵🇪
Clínica Virgen Milagrosa, Lima, Peru

Etoricoxib Versus Ibuprofen in Third Molar Extraction Pain

Phase 4

Conditions: Dental Extraction

Interventions: Drug: etoricoxib
Drug: ibuprofen

First Posted Date: 2009-03-04

Last Posted Date: 2009-03-04

Lead Sponsor: Universita di Verona

Target Recruit Count: 110

Registration Number: NCT00855777

Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)

Phase 3

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Etoricoxib 90 mg
Drug: Etoricoxib 120 mg
Drug: Ibuprofen 600 mg
Drug: Matching Placebo for Etoricoxib 120 mg
Drug: Matching Placebo for Etoricoxib 90 mg
Drug: Matching Placebo for Ibuprofen
Drug: Morphine
Drug: Oxycodone

First Posted Date: 2009-01-09

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 776

Registration Number: NCT00820027

Etodalac, Etoricoxib and Dexamethasone for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery

Not Applicable

Conditions: Trismus
Edema
Pain

Interventions: Drug: Etodalac, Etoricoxib and Dexamethasone

First Posted Date: 2008-11-19

Last Posted Date: 2008-11-19

Lead Sponsor: Tel-Aviv Sourasky Medical Center

Target Recruit Count: 80

Registration Number: NCT00793052

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy